September 2025 in “Cureus” GLP-1 agonists may help treat certain skin conditions.
May 2024 in “International Journal of Dermatology” More research is needed to understand if GLP-1 agonists affect hair health.
59 citations
,
August 2021 in “Frontiers in Endocrinology” GLP-1 receptor agonists, like Dulaglutide, Liraglutide, and Semaglutide, have potential benefits beyond the pancreas, including neuroprotection, pain suppression, cardiovascular protection, obesity management, and cancer treatment, but there are concerns about pancreatitis and pancreatic cancer risks.
1 citations
,
September 2025 in “Dermatology and Therapy” GLP-1 RAs help with diabetes and skin issues but can cause skin reactions and surgery challenges.
April 2026 in “American Journal of Clinical Dermatology” GLP-1 receptor agonists may help or harm hair health, needing more research.
GLP-1 receptor agonists for weight loss may cause hair loss, especially in women.
January 2026 in “Skin Appendage Disorders” Hair shedding is common in GLP-1 users, affecting treatment adherence.
October 2025 in “JEADV Clinical Practice” GLP-1 receptor agonists may increase the risk of a specific type of hair loss called androgenetic alopecia.
February 2025 in “Skin Appendage Disorders” GLP-1 receptor agonists can cause skin reactions, facial fat loss, and hair loss, but may help with wound healing and skin conditions.
February 2026 in “JAAD International” 1 citations
,
January 2025 in “ARC Journal of Dermatology”
February 2025 in “medRxiv (Cold Spring Harbor Laboratory)” GLP-1 agonists may increase the risk of hair loss.
5 citations
,
August 2024 in “Cureus” GLP-1 receptor agonists help women with PCOS lose weight and improve health, but more research is needed on long-term effects.
October 2025 in “EMJ Dermatology” GLP-1RA therapy may increase the risk of hair loss.
GLP-1 receptor agonists can cause skin and hair issues due to rapid weight loss, but these can be managed with proper care and treatments.
January 2025 in “Journal of the European Academy of Dermatology and Venereology” Newer GLP-1 drugs like semaglutide may cause hair loss.
October 2025 in “International Journal of Dermatology” GLP-1 receptor agonists may cause hair loss, but regrowth is rare.
August 2024 in “Nutrition Bulletin” GLP-1 receptor agonists help with weight loss but need to be combined with other treatments for best results.
April 2026 in “Journal of Clinical Medicine” GLP-1 RAs may help wound healing but can also cause faster facial aging and skin issues.
April 2026 in “Science Progress” GLP-1 therapies, especially semaglutide and tirzepatide, may cause hair loss, particularly in women and with rapid weight loss.
37 citations
,
March 2006 in “Regulatory Peptides” Mice skin has components that could help with hair growth and might be used for diabetes treatment.
November 2024 in “Circulation” GLP1-RAs may have higher reports of suicide and hair loss, but no strong evidence links them to these issues.
4 citations
,
September 2025 in “Biomolecules” The effect of GLP-1 RAs on erectile function is unclear and needs more research.
12 citations
,
June 2024 in “JAAD Case Reports” Tirzepatide may improve hair loss by reducing insulin resistance.
2 citations
,
December 2022 in “Journal of Clinical Medicine” Medications for glucose metabolism and weight control, combined therapy options, and herbal medicines may help regulate menstrual cycle in adolescents with PCOS.
1 citations
,
March 2025 in “Journal of Investigative Dermatology” Metabolic issues may trigger lymphocytic cicatricial alopecia, and treatments targeting these issues could help.
A rash from semaglutide may be due to propylene glycol, not the drug itself.
July 2023 in “Journal of Clinical Medicine” Tirzepatide might help manage PCOS in obese patients but needs more research to confirm safety and effectiveness.
December 2024 in “African Journal of Biomedical Research” Combining lifestyle changes and medication is most effective for managing PCOS symptoms.
March 2026 in “Frontiers in Medicine” New therapies for rare skin diseases show promise but need more research.